Argenx announced plans to acquire Unnatural Products (UNP) in a transaction valued at $550 million upfront, expanding beyond its antibody-centric portfolio. The deal brings UNP’s macrocyclic peptide discovery and development platform into Argenx, positioning the company for oral, long-acting peptide medicines. The acquisition also continues the relationship between the two firms, which began with a research collaboration. UNP will operate as a dedicated macrocyclic peptide discovery hub from its Santa Cruz base, while Argenx integrates the technology to pursue new targets in immunology and other immune-mediated areas.